Phase 3 study of the efficacy and safety of the microbicide Carraguard in preventing HIV seroconversion in women

Trial Profile

Phase 3 study of the efficacy and safety of the microbicide Carraguard in preventing HIV seroconversion in women

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs PC 515 (Primary)
  • Indications HIV infections; Human papillomavirus infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 May 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 06 Dec 2008 Results were reported in the Lancet.
    • 06 Dec 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top